medigraphic.com
ISSN 1028-4818 (Electronic)

2020, Number 4

<< Back Next >>

Mul Med 2020; 24 (4)

Risk factors for cardiovascular diseases in patients up to 50 years old

Berdú SJ, Chacón PT, Fonseca AA, Pérez RRM

Language: Spanish
References: 25
Page: 772-7981
PDF size: 228.84 Kb.


ABSTRACT

Introduction: cardiovascular diseases are the main cause of morbidity and mortality, despite improvements in clinical results and the introduction of new drugs.
Objective: to evaluate the influence of risk factors in the development of cardiovascular diseases in adults aged up to 50 years.
Method: a retrospective analytical study of cases and controls (relation 1 case: 1 control) was carried out in patients with the diagnosis of cardiovascular disease (CVD) who were admitted to the "Carlos Manuel de Céspedes" Provincial University Hospital of the Bayamo municipality, Granma, from January 5, 2017 to December 31, 2018.
Results: male sex (OR: 1.00; CI: 0.449-2.087; p: 0.999) and alcoholism (OR: 0.53; CI: 0.012-1.236; p: 0.000) showed no association with the risk of developing however, a CVD increased the mentioned risk more than five times (OR: 5.52; CI: 2,326-13,106; p: 0.000). The comorbidity with the highest strength of association was shown by HTN (OR: 36.42; CI: 213,118-51,161; p: 0.000) while C-reactive protein (OR: 6.01; CI: 2,640-13,681; p: 0.000) was the biomarker with the highest association with the risk of developing a CVD. Likewise, the multivariate analysis showed that the factors with the greatest independent influence to develop a CVD were C-reactive protein by increasing the risk to 49.35 (CI: 3.968-61.906; p: 0.000) followed in order of importance by HT (OR : 25.4; CI: 14.481-44.118; p: 0.000) both very significantly.
Conclusions: a model was obtained to estimate the risk of developing cardiovascular disease useful as an instrument for clinical and epidemiological surveillance, by identifying subjects with a greater probability of becoming ill.


REFERENCES

  1. Sanchis Gomar F, Pérez Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.

  2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. RevEspCardiol2016; 69(10): 939e1-e87.

  3. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud, 2018. [Internet]. 2019 [citado 9/5/2020]. Disponible en: https://files.sld.cu/bvscuba/files/2019/04/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2018-ed-2019-compressed.pdf

  4. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke-2019 update. A report from the American Heart Association. Circulation2019; 139(10): e56-e528.

  5. Alfonzo Guerra JP. Retos de la paradoja mayores riesgos y más expectativa de vida vs realidad en la salud. Rev Cubana Med 2016; 55(2):159-66.

  6. Borges ML, Monserrate ÁI, Barroso BR, Turro PA, de la Torre NE. Algunos de los nuevos factores predictores de riesgo cardiovascular. Panorama Cuba y Salud 2016; 11(3): 51-5.

  7. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction. Circulation 2018; 138(20): e618-e651.

  8. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland Coats JGF, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart J 2016; 37(27): 2129–2200.

  9. Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: Implications for electronic cigarette use. Trend in Cardiovascular Medicine 2016; 26(6): 515-23.

  10. Bell S, Daskalopoulou M, Rapsomaniki E, George J, Britton A, Bobak M, et al. Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records. BMJ. 2017; 356: 909.

  11. Sabatine M, Cannon CP. Approach to the Patient with Chest Pain. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald’s Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia: Saunders; 2015. p. 1057–67.

  12. Lee W, Hwan SH, Choi H, Kim H. The association between smoking or passive smoking and cardiovascular diseases using a Bayesian hierarchical model: based on the 2008-2013 Korea Community Health Survey. EpidemiolHealth[Internet]. 2017 [citado 4/5/2020]; 39. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723911/pdf/epih-39-e2017026.pdf

  13. Pisinger C, Dossing M. A systematic review of health effects of electronic cigarettes. Prev Med 2014; 69: 248–60.

  14. Álvarez Aliaga A, Rodríguez Blanco LH, Fonseca Aguilera AA, Fonseca Muñoz JC, López Costa C, Hernández Galano ME. Factores de riesgo de daño a órgano diana por hipertensión arterial. MAPFRE Med 2007; 18(3): 190-200.

  15. Álvarez Aliaga A, González Aguilera JC, Maceo Gómez LR. Factors associated to hypertensive heart disease development: a prospective cohort study in Bayamo, Cuba. Medwave 2016; 16(6): e6492.

  16. Victor RG. Arterial hypertension. En: Lee Goldman L, Schafer AI, editors. Goldman-Cecil Medicine. 25th ed. Philadelphia, PA: Elsevier Saunders; 2016.p. 381-97.

  17. Ukpabi OJ, Ewelike ID. The eighth joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure (joint national committee-8) report: Matters arising. Nig J Cardiol 2017; 14(1):15-8.

  18. Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest 2017; 127(1): 83-93.

  19. Pérez-Bedoya JP, Gallego-Lopera N, Velarde-Hoyos CA, Franco-Hincapié L, Betancur-Salazar KJ, Valencia-Duarte AV. Efecto de la hiperglucemia en el síndrome coronario agudo y sus implicaciones en el tratamiento antiagregante plaquetario. Iatreia 2019; 32(2):113-125.

  20. Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA Cardiol2018; 3(4):280–287.

  21. Ridker PM, Nina P. Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction the Reynolds Risk Score for Men. Circulation 2008; 118(22):2243-51.

  22. Pérez Fernández Y, Soto García A. Factores de riesgo de las enfermedades cardiovasculares. [Tesis]. Madrid. Universidad Complutense de Madrid; 2017. [citado 20/6/2019]. Disponible en: http://147.96.70.122/Web/TFG/TFG/Memoria/ANA%20SOTO%20GARCIA.pdf

  23. Lönnberg L, Ekblom-Bak E, Damberg M. Reduced 10-year risk of developing cardiovascular disease after participating in a lifestyle program in primary care. Ups J Med Sci 2020; 20: 1-7.

  24. Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016;374(21):2032-43.

  25. Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia2016; 8(2): 56–61.




2020     |     www.medigraphic.com